Assesment of patient's perspective on treatment free remission in CML: A Turkish multicenter cohort
![Thumbnail](/xmlui/bitstream/handle/20.500.12511/10623/Aydin-Berrin-2022.pdf.jpg?sequence=3&isAllowed=y)
View/ Open
Access
info:eu-repo/semantics/openAccessDate
2022Author
Mutlu, Yaşa GülGüvenç, Birol
Serin, İstemi
Balık Aydın, Berrin
Alacacıoğlu, İnci
Güven, Serkan
Sevindik, Ömür Gökmen
Metadata
Show full item recordCitation
Mutlu, Y. G., Güvenç, B., Serin, İ., Balık Aydın, B., Alacacıoğlu, İ., Güven, S. ... Sevindik, Ö. G. (2022). Assesment of patient's perspective on treatment free remission in CML: A Turkish multicenter cohort. Blood içinde (11490-11490. ss.). https://dx.doi.org/10.1182/blood-2022-165732Abstract
Treatment free remission (TFR) is one of the main goals of therapy in Chronic Myeloid Leukemia (CML). Patient perspective and expectations have an indicative effect on discontinuation decisions. We analyzed 116 CML patients' perspective on TFR and factors that associated with willingness for tyrosine kinaz inhibitor (TKI) discontinuation from four different center in Turkey based on a national survey. Patients in our cohort had 7.8% awareness of TFR and after brief information willingness to attempt TFR has been reached to 58.9% in all population. Shorter disease duration was associated with enhanced willingness to attempt discontinuation in multivariate analyses (p=0.031). Most common patient related limitation for TKI discontinuation decision was anxiety about disease relaps and TKI resistance. Even disease relaps in TFR means molecular and detectable with close monitoring, patients still had considerable concerns about TKI discontinuation.
WoS Q Kategorisi
Q1Source
BloodVolume
140Issue
Supplement: 1Collections
- Bildiri Koleksiyonu [65]
- Bildiri Koleksiyonu [516]
- WoS İndeksli Yayınlar Koleksiyonu [6677]